Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lurasidone in Bipolar I Depression
NCT04383691Phase 3Terminated
- Sponsor
- Sumitomo Pharma
- Start
- Dec 2020
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in bipolar I disorder comparing Lurasidone with Placebo (2 arms). Primary endpoint: Montgomery-Asberg Depression Rating Scale at 6 weeks. Started Dec 2020; status: terminated.
02
Drugs
lurasidone
03
Conditions
bipolar I disorder
Beyond the preview
Go deeper on NCT04383691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04383691.